Aaron Tachibana joined Personalis as Chief Financial Officer in March 2019, with more than fifteen years of executive financial management experience at large, medium, and small cap public and private companies. Prior to Personalis, Mr. Tachibana was Chief Financial Officer at Lumentum from August 2015 to September 2018. Lumentum is a publicly listed optical and [...]
Personalis, Inc. to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019 Menlo Park, CA – March 31, 2019 – Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present one oral presentation and five posters at the American Association for Cancer Research (AACR) [...]
Personalis, Inc. to Present at ICI-IO Combinations Summit 2019 Menlo Park, CA – March 18, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at ICI-IO Combinations Summit 2019 in Boston on Wednesday, March 20, 2019 at 2:30 PM, EDT. The presentation, [...]
Personalis, Inc. to Present at the World Immunotherapy Congress USA 2019 Menlo Park, CA – February 28, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming World Immunotherapy Congress USA, which is part of the Festival of Biologics USA, [...]
Personalis, Inc. to Present at the 2019 Immuno-Oncology 360 Conference in New York Menlo Park, CA – February 5, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming Immuno-Oncology 360° Conference in New York on Thursday, February 7, 2019 at [...]
RepertoireID An analytical module of the ImmunoID NeXT Platform Comprehensive Profiling of the TCR Repertoire T-cells are one of two types of lymphocytes (the other being B-cells) that are active cellular participants in the adaptive immune system. T-cells express T-cell receptors (TCRs) on their surface, and these receptors function [...]
2018 SITC: More Sensitive Identification of T-cell Receptor Beta Arrangements with an Augmented Transcriptome Method With the increase in development and use of immunotherapies, there is also an increasing need for comprehensive immuno-genomic profiling of tumors to identify new potential biomarkers. This includes profiling of the T-cell receptor (TCR), which has traditionally not been [...]
Personalis Appoints Biotech Industry Executive Clinton Musil as Chief Business Officer Menlo Park, CA – January 3, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced the appointment of Clinton Musil as Chief Business Officer. Mr. Musil will focus initially on financing strategy. As a member of Personalis’ [...]
Clinton Musil joined Personalis in January 2019 as Chief Business Officer. Mr. Musil previously worked at ARMO Biosciences, where he oversaw the Company’s $147 million initial public offering and $1.6 billion sale to Eli Lilly. Clinton has expertise in corporate finance and mergers and acquisitions (M&A) from the healthcare industry, including raising several billion dollars [...]
2018 SITC: Improving Neoantigen Identification for Therapeutic and Diagnostic Use in Immuno-Oncology Using Mass Spectrometry and Machine Learning Neoantigens are increasingly critical in immuno-oncology as therapeutic targets for neoantigen-based personalized cancer vaccines (PCVs) and as potential biomarkers for immunotherapy response. However, the methods for identifying which neoepitopes are more likely to provoke an immune [...]
